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)ere are few studies about the pharmacokinetics of the low-molecularmass carotenoids crocetin or crocin isomers from saffron (Crocus
sativus L.). None has been performed with a galenic preparation of a standardised saffron extract. )e aim of the present research work
was to study the effect of in vitro digestion process on the main bioactive components of saffron extract tablets and the corresponding
pharmacokinetic parameters in humans. Pharmacokinetics were calculated collecting blood samples every 30min during the first 3 h
and at 24 h after administration of two different concentrations (56 and 84mg of the saffron extract) to 13 healthy human volunteers.
Additionally, an in vitro digestion process was performed in order to determine the bioaccessibility of saffron main bioactive com-
pounds. Identification and quantification analysis were performed by HPLC-PAD/MS. Digestion resulted in 40% of bioaccesibility for
crocin isomers, whereas, safranal content followed an opposite trend increasing about 2 folds its initial concentration after the digestion
process. Crocetin in plasma was detected in a maximum concentration (Cmax) in blood between 60 and 90min after oral consumption
with dose-dependent response kinetics, showing that crocin isomers from galenic preparation of saffron extract are rapidly transformed
into crocetin. )e results showed that this tested galenic form is an efficient way to administer a saffron extract, since the observed
crocetin Cmax was similar and more quickly bioavailable than those obtained by other studies with much higher concentrations
of crocetin.
1. Introduction
Saffron, dried stigmas of Crocus sativus L. (Iridaceae), was
traditionally used as food spice worldwide to provide colour,
taste, and odour in several food recipes. Saffron is charac-
terised by a pool of bright yellow-coloured crocins, water-
soluble carotenoids of 20 atoms of carbon [1], a bitter taste
attributed to picrocrocin [2, 3], and its subtle aroma, chiefly
due to the presence of safranal [4, 5].
Besides the culinary role of saffron, safranal and crocin
isomers show bioactive properties with several therapeutics
and pharmacological applications [6–8], altogether with
other antioxidant compounds such as kaempferol derivatives
[9, 10]. By contrast, the interest of picrocrocin is limited since
it is poorly absorbed in the gut [11]. Nowadays, the clinical
evidences of saffron extracts have been accumulated and has
been postulated as a complementary therapy in several
medical conditions. In particular, to delay the occurrence of
the symptoms and effects of degenerative ocular diseases [8]
and to prevent and treat mood disorders and mild-to-severe
depression without side-effects, even in people with unre-
mitted depression treated with antidepressant medication
[12–16]. In depression, different mechanisms of actions have
been proposed to explain the functional properties of saffron
such as reuptake inhibitors of monoamines, N-methyl-D-
aspartate receptor (NMDA) antagonism, and gamma-
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aminobutyric acid (GABA) agonism [17, 18]. In addition, the
antioxidant capacity of saffron may contribute to balance the
oxidative stress in depressive patients [19]. )e anti-in-
flammatory, antioxidant, and neuroprotective properties
may explain its positive effect on the eye [8, 20].
)e published beneficial effects of saffron extracts led to
better understand the role of its bioactive compounds, but
their bioaccessibility and bioavailability were investigated
mostly only in invitro experiments, cell models, and animal
tests. During in vitro digestion of an aqueous saffron extract,
a significant reduction of crocin concentration was observed,
mainly trans-crocins, in a dependent process on the phys-
iological pH, temperature, and time of digestion [21]. In
experiments with Caco-2 cells, it was found that picrocrocin
and crocin isomers were bioaccesible with different efficacy;
picrocrocin was poorly or almost not absorbed by the in-
testinal cells, whereas crocins showed a high bioavailability
in crocetin form after its deglycosylation due to an enzy-
matic action [11, 22]. )e in vitro studies results were
confirmed in animals. After oral dosing of crocins or cro-
cetin, no crocin but crocetin was measured in the rat and
mouse plasma as free, mono-, and diglucuronide conjugates
[23, 24]. Most of this information has been evaluated with
purified compounds, crude laboratory-extracts with diverse
composition, or raw saffron stigmas in food. )e in vitro
digestion studies report that the bioaccessibility of crocins
depends on different factors such as the dietary ingredient
which are consumed with or its combination with other
bioactive compounds [25, 26].
Despite the growing interest in the use of saffron ex-
tracts as a functional product in mental health, there are
few studies about the pharmacokinetics of its bioactive
substances in humans. One of them determined the cro-
cetin appearance in the plasma samples of 4 human vol-
unteers after the intake of a cup of 200mg saffron infusion
[27]. )e two others tested the kinetics of crocetin in
plasma in volunteers that consumed crocetin purified from
plant sources at high concentrations [28, 29]. None of them
studied the pharmacokinetics of a pharmacological prep-
aration of a standardised saffron extract. A study is needed
for a better understanding of the effectiveness and the
relation dose-response, being particularly interesting for
setting directions for use, doses, and the development of
new products based on this extract. )erefore, the aim of
this study was to investigate the in vitro bioaccessibility of
the main bioactive components of a commercial saffron
extract (affron®) during the digestion process and thecorresponding pharmacokinetics in humans after oral
administration.
2. Materials and Methods
2.1. Materials and Reagents. )e saffron (Crocus sativus L.)
stigmas were extracted in the factory of Pharmactive Biotech
Products S. L. in Madrid (Spain) to produce the commercial
saffron extract, branded as affron®, and dosed in tablets aspreferred galenic form for the in vitro digestion and the
clinical trial. Each tablet contained 14mg of dried affron®standardised to ≥3.5% lepticrosalides®, defined as the
content of bioactive compounds including safranal and
crocin by HPLC [12, 13], together with the following ex-
cipients: microcrystalline cellulose, calcium hydrogen
phosphate, povidone, croscarmellose sodium, colloidal an-
hydrous silica, and magnesium stearate as excipients and
coated with hypromellose (HPMC), macrogol (PEG) 8000,
and carnauba wax.
Safranal, crocetin, p-nitroaniline, and digestive en-
zymes were purchased fromMerck (Darmstadt, Germany).
Kaempferol was purchased from Extrasynthese (Genay,
France), and trans-crocin-4 was purchased from Phytolab
(Vestenbergsgreuth, Germany). All the solvents used for
the chromatographic analyses were of HPLC grade and
purchased from Merck and VWR (Pennsylvania, United
States).
2.2. InVitroDigestion. Abiotic in vitro digestion was carried
out according to Hollebeeck et al. in three stages (oral,
gastric, and intestinal digestion) with 28mg of affron®(equivalent to 2 tablets). Briefly, the salivary step runs for
5min at pH 6.9 and 37°C, under aerobic conditions with 3.9
units α-amlylase/ml. )en, the samples were transferred for
90min to the gastric step at pH 2 and 37°C with 71.2 units
pepsin/ml under anaerobic conditions. Finally, the duodenal
step was set for 150min at pH 7 and 37°C, with 9.2mg
pancreatin/ml and 55.2mg bile extract/ml under anaerobic
conditions. Samples were taken from every steps and were
centrifuged at 7000 g for 40min at 4°C. )e soluble fractions
were frozen at − 20°C, freeze-dried and the resulting dry
powders were stored in a dark, dry place until analysis [30].
All samples were analysed at least in duplicate.
2.3. HPLC-PAD/MS Analyses of Saffron Extracts from the In
Vitro Assay. Peak identification of affron® compounds wasperformed by mass spectrometry (MS) using an Agilent
series 1100 HPLC, coupled to a mass-quadrupole detector
(Hewlett-Packard, series 1100 MSD), with an electrospray
ionization source (ESI) set at the following conditions: mass
range, from 50 to 1500 amu; drying gas flow, 10 L/min;
drying gas temperature, 340°C; nebulizer pressure, 40 psig;
vaporizer temperature, 150°C; capillary tension, 2000V;
charge tension, 2000V. Ion current acquisition was operated
at both, positive and negative modes, with precision, ac-
curacy, and detection limits as in [31].
High-performance liquid chromatography (HPLC)
analysis of bioactive components from initial and digested
saffron extract was performed using an Agilent Technologies
1220 Infinity series system equipped with a photodiode array
detector (PAD) according to Kell et al. [12], while the analysis
of crocetin was according to Umigai et al. [28]. )e reference
substances safranal, trans-crocin-4, kaempferol, and p-
nitroaniline were used to plot external calibration curves for
the quantification of safranal, crocetin-crocin isomers,
kaempferol derivatives, and picrocrocin, respectively.
To estimate the percentage of bioaccessibility of the main
bioactive compounds of affron®, an equation was usedaccording to Ordoudi et al. [26].
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2.4. Clinical Trial, Study Design, and Procedures. A single
dose, randomized, double blinded study was used to evaluate
the pharmacokinetics of two different saffron doses (56mg
and 84mg). )e randomization code was generated by
Random Allocation Software, sealed envelope (London,
UK). Enrolled participants were then allocated to one of two
groups: group 1: consumed 4×14mg of affron® tablets(56mg single dose); group: 2 : 6×14mg of affron® tablets(84mg single dose).
)is study was conducted in accordance with the
ethical approval from Bellberry Limited ethics committee
(approval number: 2016-04-305-A4). All participants
provided written informed consent and were screened for
inclusion and exclusion criteria prior to the conduct of the
study.
)e subjects of the pharmacokinetics were adult male
(n� 5) and female (n� 8; nonpregnant and nonlactating)
healthy volunteers of 18–30 years age. All participants self-
reported to be in normal physical health (BMI< 30) and
passed the exclusion screening. Exclusion criteria included
suffering clinically significant medical condition, such as, but
not limited to, cardiovascular, neurological, psychiatric,
renal, immunological, endocrine (including uncontrolled
diabetes or thyroid disease), or uncontrolled haematological
abnormalities. Other exclusion criteria were the use within
the past 3 months of the tested compounds and/or anti-
oxidants; no current use of prescription medications except
the oral contraceptive pill in women; and known allergy to
any tested compound and/or antioxidant.
All participants were advised to fast from 10 : 00 pm
prior to the study until the collection of the first blood
sample. Fasting was broken immediately after dosing the
corresponding tablets. At time 0 h and at 4 h after dosing,
balanced breakfasts (410 kcal, approximately 30% of them
from fats) and lunches (625 kcal, approximately 30% from
fats) were served at the center. )e meals were poor in
carotenoids. Subjects remained onsite for the full first 6
hours of sample collection and returned to the center again
for the 24 h samples. Subjects were monitored and asked to
report any possible side-effects experienced due to intake of
the tablets during the whole 24 h time after the intake of the
tablets.
2.5. Analytical Procedure for Crocetin in Plasma
2.5.1. Plasma Sample Collection. For crocetin pharmaco-
kinetic analysis, blood samples (3ml collected into tubes
with EDTA) were drawn prior to affron® supplementation(time 0 h), between time 30 and 180min at every 30min and
24 h after supplementation. )e blood tubes were briefly
mixed by inversion and put on ice and centrifuged (600 g,
4°C for 10min) to separate the plasma.)e EDTA-plasma of
every sample was carefully removed in 3 aliquots (500 μl
each) and stored at − 20°C for less than 48 h before being
finally transported and stored at − 80°C.
2.5.2. Sample Extraction. Plasma samples were extracted
based on the method described and validated by
Mohammadpour et al. [29]. Briefly, plasma samples were
thawed to room temperature. )en, 20 μl of an internal
standard solution of 13-cis-retinoic acid and 120 μl aceto-
nitrile were added to 100 μl of sample. )e samples tubes
were capped and vortexed for 10 s and put on ice for 5min.
)e samples were then gently rotated for 10 minutes before
centrifuging at 12000 g for 10min. )e supernatant was
collected and analysed by HPLC.
2.5.3. Recovery. )e efficiency of the extraction process was
estimated by the measure of the residual amount of the
internal standard, and 13-cis-retinoic acid was recovered
after the analysis. )e recovery percentage was then applied
to the results to calculate the true concentration of crocetin
in the samples.
2.5.4. Identification and Quantification of Crocetin in Plasma
Samples. )e chromatogram of a sample of pure standard
crocetin and its typical absorption wavelength were used to
identify and confirm the crocetin peak in every analysis, as
shown in Mohammadpour et al. [29].
)e crocetin concentration in biological samples was
calculated using a standard linear curve at several crocetin
concentration and the Shimadzu software for chromatogram
analysis. All samples fell within the range of the linear
standard curve (concentration (μg/ml)� (AUC+ 131.56)/
9475). )e intra-assay precision CV was 4.8%, and the
interassay variability and precision CV were 7.3%, with a
blood detection limit of 0.05 μg/ml.
2.6. Pharmacokinetic Parameters and Statistical Analysis.
Pharmacokinetic parameters were derived using GraphPad
Prism 7.0 (California, USA). Data are represented as the
mean± SD and analysed using the SPSS 17.0 statistical software
(SPSS Inc., Chicago, USA). Significance of differences at
p≤ 0.05 was determined by one-way ANOVA (Friedman test),
and the Bonferroni test was used as post hoc analysis.
3. Results
3.1. Analytical Composition of the Saffron Extract.
Individual identification of each component of the com-
mercial saffron extract affron® was done by their charac-teristic UV absorbance peaks at 250, 310, and 440 nm, and
their mass/charge relation, as in Table 1, shows the presence
of the different bioactive components naturally present in
saffron (Crocus sativus L.).
Among the main bioactive compounds found in affron®,at 250 nm, picrocrocin was detected, with characteristic
quasimolecular (353.2m/z) and fragment ions (151m/z,
123m/z) in ESI +mode. Kaempferol diglucoside was also
identified at 250 nm, with its characteristic UV-Vis spectrum
(maximum absorbance at 266 and 347 nm), together with
typical quasimolecular ions in ESI+(633.2m/z) and ESI−
(609m/z) modes. )ese results were in accordance with
those obtained with saffron stigmas by Lech et al. [31].
Safranal was identified according to its retention time
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(identical to the standards) and UV-Vis spectra, with a
characteristic maximum absorbance peak at 310 nm, as
shown at Table 1.
With the previous method, crocetin detection was not
possible due to interferences with crocin isomers. Residual
crocetin was detected and identified by the identical re-
tention time to the standard and its UV-Vis spectra, with a
maximum absorbance peak at 440 nm.
3.2. InVitroDigestion. As can be observed in Table 2, during
the digestion process, the bioactive components of affron®were affected in a different manner. Referring to the volatile
fraction, after the digestion process, safranal content sig-
nificantly increased about two folds compared to the initial
conditions (from 0.04 to 0.08%; Table 2), while the pic-
rocrocin content decreased by 19%. )is opposite behaviour
is due to the mutual relation between both compounds.
Safranal is formed by picrocrocin, and part of it may have
been degraded during the digestive process, rising the
safranal concentration. Compared with safranal, crocin
isomers followed an opposite trend after the digestion
process, which significantly reduced their concentration
with a bioaccessibity of 40.77%. )is great decrease in its
content happened at the second stage; crocins were very
sensitive to stomach conditions, trans-crocin-4 being the
most sensitive crocin isomer to the acid-pepsin environment
during gastric digestion (84% reduction.)
Furthermore, the whole in vitro digestion process (sal-
ivary, stomach, and duodenal steps) did not increase the
concentration of crocetin compared to the initial compo-
sition of affron®, and its concentration remained 2 orders ofmagnitude lower compared with crocins. In addition,
kaempferol derivatives content was also not affected during
digestion, with high bioaccessibility data (69.23%; Table 2).
3.3. Pharmacokinetics with Humans. )e demographic data
of the subjects are shown in Table 3. All the adults included
in the different study groups were young and in good shape,
and none of the participants reported adverse events during
the study.
Crocins, picrocrocin, and safranal were not detected in
plasma. Only crocetin was enough concentrated to be
identified and quantified at the tested blood samples (Ta-
ble 4). )e crocetin concentration in plasma up to 60 and
90min, respectively, and then gradually decreased after-
wards down to the HPLC-PAD quantification limit in 3 h
(Figure 1). Twenty-four hours after affron® intake, thecrocetin concentration remained below the detection limit.
Table 4 represents the differences in the pharmacokinetic
parameters after the intake of the two different affron® dosages.At baseline, the two initial experimental groups showed low
crocetin concentrations. Differences in AUC(0-3h) and Cmax
between the two doses were statistically significant according to
the Friedman test (p< 0.05). )e average maximum




(nm) ESI+ (m/z) ESI− (m/z)
7.6 Picrocrocin 251 511.2; 365.1; 353.2; 337.1; 329.1; 185.1; 159.9;151.1; 123.0; 81.3
1480.8; 667.2; 517.1; 385.0;
181.2; 153.1
11.5 Kaempferoldiglucoside 266; 347 633.2; 347.1 609.0; 284.0
22.1 trans-crocin-4 261; 323; 441; 464 999.4; 675.2; 511.2; 347.1 1336.2; 651.2; 326.8; 283.1
26.7 trans-crocin-3 261; 323; 440; 463 837.4
30.7 trans-crocin-2′ 261; 328; 440; 464 675.2; 593.0; 513.2; 351.1; 130.1; 102.2; 74.1
33.9 Safranal 313 — —
36.2 cis-crocin-4 225; 262; 325; 433;456 999.4; 821.3; 668.3; 611.0; 391.0; 347.0 651.2
37.6 trans-crocin-2 260; 322; 433; 458 675.2; 541.1 651.2; 327.1; 311.1; 283.1
Bold numbers indicate coincidences in the molecular fractions obtained in [30].
Table 2: Bioactive molecules content expressed as percentage (%, dry basis) found in affron® before and after in vitro digestion process atsalivary, gastric, and duodenal steps.




Safranal 0.04± 0.01a 0.03± 0.00a 0.21± 0.01c 0.08± 0.01b 200.00
t-crocin-4 1.66± 0.04b 1.11± 0.43b 0.26± 0.03a 0.20± 0.04a 12.05
Total crocins 3.63± 0.05b 3.43± 0.12b 1.87± 0.35a 1.48± 0.22a 40.77
Kaempferol diglucoside 0.13± 0.01b,c 0.14± 0.01c 0.12± 0.01b 0.09± 0.01a 69.23
Picrocrocin 3.21± 0.07c 3.14± 0.11c 2.07± 0.02a 2.61± 0.05b 81.31
Crocetin 0.03± 0.01a 0.02± 0.01a 0.03± 0.01a 0.02± 0.01a 66.67
Data are represented as mean± SD. Different letters within a column (a–c) indicate significant differences (p< 0.05) of the bioactive component of affron® in
every step during the digestion process.
4 Evidence-Based Complementary and Alternative Medicine
concentration (Cmax) of crocetin was between 0.26 and 0.39μg/
ml for the minimum (56mg) and maximum (84mg) dosages,
obtained at 60 and 90 min, respectively, after oral intake
(Figure 1).
4. Discussion
During in vitro digestion of affron® tablets, changes in theconcentrations of the different bioactive compounds of
interest could be observed. )e increase of safranal content
and decrease of picrocrocin concentration (Table 2) were
because the picrocrocin hydrolysis to safranal occurred at
moderate temperature and acidic pH during this in vitro
assay [32,33]. On the other hand, kaempferol derivatives
content did not decrease much during in vitro digestion.
)ese results are in line with those obtained by Yang et al.
[34], that described the changes during digestion of some
kaempferol derivatives from a sample of kale, concluding
that 69.4% of them were bioaccessible. Goh and Barlow also
obtained similar results in their experiments, which showed
a decrease of about 5% after digestion compared with the
initial flavonoid content [35]. In addition, the significant of
observed of crocin isomer concentration was probably due
to the combination of different factors such as the physi-
ological temperature (37°C) and pH changes at gastric and
intestinal digestion phases, respectively [21]. )e results
obtained with the saffron extract tablets were similar to that
by Kyriakoudi et al., showing a significant decrease of
apocarotenoids, especially and more accelerated in the
crocin trans-form. As a result of the extensive degradation,
the crocin bioaccessibility after in vitro digestion was less
than 50%.)e experimental conditions were essentially as in
Kyriakoudi et al. [21], except for stomach simulation du-
ration, which was 50% longer in this work. Modifications
suffered by crocins would happen quickly, and an extended
period of treatment under acid conditions did not mean a
further modification or alter much its content. In addition,
the agreement between our results with a standardised
saffron extract and those obtained with in vitro digestion of
stigmas in a liquid formulation [21] suggest that neither the
direct compression tablets manufacturing nor the tablet
excipients did affect the quick solubilisation of crocins.
During the in vitro digestion, the crocetin concentration
compared with the initial composition of affron® present atthe galenic formulation was not affected, proving that the
formation of crocetin found in blood was not due to a simple
chemical modification of the preexisting crocins but require
the presence of enzymes from epithelial cells in the gas-
trointestinal tract, which hydrolyses the crocin isomers
[22–24]. In order to study the appearance of crocetin in
blood after oral consumption of an affron® tablet, the studywas completed by means of crocin isomers pharmacoki-
netics in healthy volunteers.
Picrocrocin was absent in plasma, confirming its poor
absorptivity [11]. Safranal was not detected or appeared
below the detection limit in plasma, likely due to the very low
amount of the substance in the tablet composition. Crocetin
Table 3: Baseline demographic details of participants.
Demographics Total (N� 13)
Treatment groups
affron® 56mg (n� 7) affron® 84mg (n� 6)
Mean age (SD) 23.6 (2.9) 23.0 (2.0) 24.6 (3.9)
Age range (years) 19–30 20–26 19–30
Gender (number, %)
Female 8 (61.5%) 4 (57.1%) 4 (66.6%)
Male 5 (38.5%) 3 (42.9%) 2 (33.4%)
Weight (SD)
Female 59.0 (4.2) 58.9 (3.7) 59.1 (4.8)
Male 83.2 (5.7) 82.9 (5.3) 83.6 (6.1)
Table 4: Pharmacokinetic parameters of crocetin plus derivatives
that come from the metabolism of crocin isomers.
Parameters
Treatment groups
affron® 56mg affron® 84mg
Tmax (min) 60 90
Cmax (μg/ml) 0.26± 0.12 0.39± 0.10
Total AUC(0-3h) (μg·h/ml) 21.07 26.15
T1/2 (h) 0.85± 0.04
CL (L/h) 2.70± 0.14
Vd (L) 3.19± 0.00
Total AUC is calculated on the crocetin concentration change from baseline
data. ke, T1/2, CL, and Vd are represented as the mean± SD. Tmax � time to
maximum concentration; Cmax �maximum concentration; AUC� area
































Figure 1: Concentration of crocetin in plasma after a single ad-
ministration dose of affron®, the commercial saffron (Crocussativus L.) extract of 4 tablets (56mg) and 6 tablets (84mg). )e
values represent mean± SD.
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was detected instead of crocin isomers in blood, in
agreement with the conclusions reported previously in
animals [23, 24] and humans [27] confirming that a prior
deglycosylation of crocin isomers is necessary before
reaching the bloodstream. Nevertheless, none of previous
works were carried out with a standardised saffron extract
in such galenic form. )e only one performed with saffron
stigmas [27] with only 4 participants and unknown
standardisation of the saffron infusion showed few re-
markable results. Despite Chryssanthy et al. not aiming at
doing a formal pharmacokinetics study, they found traces
even after 24 h of administration, obtaining the highest
crocetin concentration between 0.3 and 1.2 μg/ml [27]. )is
was in a similar range to the Cmax obtained in this study
with an equivalent dose of 2 and 3mg of crocins
correspondingly.
)ere are two other works that studied the pharmaco-
kinetics of crocetin. One of them used purified crocetin from
dried fruits of Gardenia jasminoides [28], while the other
used purified crocetin from saffron [29]. Crocetin doses in
both cases were 10-fold higher than the used in this study.
)e results obtained by Umigai et al. with G. jasminoides
crocetin was a Cmax of 0.28 μg/ml with a single oral dose of
22.5mg of crocetin [28], whereas Mohammadpour et al.
achieved aCmax of 0.35 μg/ml with a single oral dose of 16mg
of saffron crocetins [29]. Surprisingly, those data are close to
the Cmax found in this work with tablets that contained only
2–3mg crocins, giving evidence that crocetin derived from
saffron extract crocins of a tablet was more bioavailable than
the pure crocetin administration, perhaps because crocins
are more bioavailable to enterocytes for later hydrolysis and
absorption than the arrival of the crocetin itself.
)e Tmax obtained by crocetin after intake of the
commercial saffron extract affron® tablet was just one h,suggesting that crocin isomers are metabolized in a short
time such as some nutrients in healthy humans [36].
Surprisingly, the Cmax values obtained in this study and in
[29] with saffron were found much earlier than those
obtained with G. jasminoides in [28]. )e delayed bio-
availability found in gardenia crocetin may be explained by
the fact that the burden of crocetin derivates isomers in
saffron and gardenia is different. While most of the saffron
crocins are found in trans-form as seen in Table 1, some of
those from G. jasminoides are found in cis-form [37] with
specific isomers not found in saffron [38]. Differential
bioavailability has been described in isomers of the same
structural carotenoids in humans, such as in lycopene [39].
Remarkably, the obtained Tmax value found in our work is
considered much lower than that obtained from phar-
macokinetic studies of other C40 carotenoids of interest in
health such as zeaxanthin, lutein, lycopene, or β-carotene,
where several hours are required to reach the plasma
maximum concentration [39–43], showing that crocetin
presented in this galenic form is quickly absorbed than the
other carotenoids.
)e distribution volume obtained in this work was
3.18 L, which is related to compounds that bind strongly
with plasma proteins as albumin [44], reducing its free
content in blood. It correlates with the previous works which
described that crocetin binds to albumin [45, 46] and other
human serum proteins [47]. After 3 h of administration,
crocetin ceased to be detected, obtaining a plasmatic half-life
of 0.85± 0.04 h and a clearance of 2.70± 0.14 L/h. )e ob-
tained values suggest that the half-life of crocetin was very
short, and its free form in blood was no longer detected, not
in agreement with the previously observed results that could
be detected 24 h after consuming much higher amounts of
crocins [27]. )is may be because, as mentioned, its dis-
tribution volume suggests that it binds strongly to albumin,
leaving the free levels below of its detection limit of 0.05 μg/
ml [29].
)e fast presence of crocetin in blood plasma after the
administration of the saffron extract contributes to better
explain saffron beneficial effects in animal models [48]. )e
commercial standardised saffron extract affron® used in thisstudy is related to beneficial effects in depression and mood
disorders by several clinical trials at the dosage used in the
present work [13, 14, 16] and in the reduction of inflam-
matory damage in the retina in an animal model of glaucoma
[20]. )e obtained results in this study increase the interest
of saffron extract use as a new preventive therapy that re-
quires a fast-active countereffect, for instance, as “fast-track”
carotenoid in the Aged-Related Eye Disease Study (AREDS-
2) formula.
5. Conclusion
Even though crocin isomers bioaccessibility were ap-
proximately 40% after affron® tablet digestion, they areable to reach the bloodstream, with proven functional
effect, in crocetin form more quickly than other lipophilic
carotenoids of higher-molecular mass, being an inter-
esting alternative for use as in fast-acting formulations.
Besides, with a low dose of crocin from affron® tablet(2–3mg), the obtained values of Cmax of crocetin were
similar to the values obtained from other studies with
higher doses of purified crocetin. In brief, affron® galenicpresentation showed rapid absorption and high oral
bioavailability.
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formation of trans-crocetin from saffron extract (Crocus sativus
L.) and in vitro permeation through intestinal and blood brain
barrier,” Phytomedicine, vol. 22, no. 1, pp. 36–44, 2015.
[23] L. Xi, Z. Qian, P. Du, and J. Fu, “Pharmacokinetic properties
of crocin (crocetin digentiobiose ester) following oral ad-
ministration in rats,” Phytomedicine, vol. 14, no. 9,
pp. 633–636, 2007.
[24] A. Asai, T. Nakano, M. Takahashi, and A. Nagao, “Orally
administered crocetin and crocins are absorbed into blood
plasma as crocetin and its glucuronide conjugates in mice,”
Journal of Agricultural and Food Chemistry, vol. 53, no. 18,
pp. 7302–7306, 2005.
[25] R. Armellini, I. Peinado, A. Asensio-Grau et al., “In vitro
starch digestibility and fate of crocins in pasta enriched with
saffron extract,” Food Chemistry, vol. 283, pp. 155–163, 2019.
[26] S. Ordoudi, A. Kyriakoudi, and M. Tsimidou, “Enhanced
bioaccessibility of crocetin sugar esters from saffron in in-
fusions rich in natural phenolic antioxidants,” Molecules,
vol. 20, no. 10, pp. 17760–17774, 2015.
Evidence-Based Complementary and Alternative Medicine 7
[27] D. G. Chryssanthi, F. N. Lamari, C. D. Georgakopoulos, and
P. Cordopatis, “A new validated SPE-HPLC method for
monitoring crocetin in human plasma-Application after
saffron tea consumption,” Journal of Pharmaceutical and
Biomedical Analysis, vol. 55, no. 3, pp. 563–568, 2011.
[28] N. Umigai, K. Murakami, M. V. Ulit et al., “)e pharma-
cokinetic profile of crocetin in healthy adult human volun-
teers after a single oral administration,” Phytomedicine,
vol. 18, no. 7, pp. 575–578, 2011.
[29] A. H. Mohammadpour, M. Ramezani, N. T. Anaraki,
B. Malaekeh-Nikouei, S. A. Farzad, and H. Hosseinzadeh,
“Development and validation of HPLC method for deter-
mination of crocetin, a constituent of saffron, in Human
serum samples,” Iranian Journal of Basic Medical Sciences,
vol. 16, no. 1, pp. 47–55, 2013.
[30] S. Hollebeeck, F. Borlon, Y.-J. Schneider, Y. Larondelle, and
H. Rogez, “Development of a standardised human in vitro
digestion protocol based on macronutrient digestion using
response surface methodology,” Food Chemistry, vol. 138,
no. 2-3, pp. 1936–1944, 2013.
[31] K. Lech, J. Witowska-Jarosz, and M. Jarosz, “Saffron yellow:
characterization of carotenoids by high performance liquid
chromatography with electrospray mass spectrometric de-
tection,” Journal of Mass Spectrometry : JMS, vol. 44, no. 44,
pp. 1661–1667, 2009.
[32] A. M. Sánchez, M. Carmona, M. Jarén-Galán, M. I. Mosquera,
and G. L. Alonso, “Picrocrocin kinetics in aqueous saffron
spice extracts (Crocus sativus L.) upon thermal treatment,”
Journal of Agricultural and Food Chemistry, vol. 59, no. 59,
pp. 249–255, 2011.
[33] H. Himeno and K. Sano, “Synthesis of crocin, picrocrocin and
safranal by saffron stigma-like structures proliferatedin vitro,”
Agricultural and Biological Chemistry, vol. 51, no. 9,
pp. 2395–2400, 1987.
[34] I. Yang, G. K. Jayaprakasha, and B. Patil, “In vitro digestion
with bile acids enhances the bioaccessibility of kale poly-
phenols,” Food & Function, vol. 9, no. 2, pp. 1235–1244, 2018.
[35] L. M. L. Goh and P. J. Barlow, “Flavonoid recovery and
stability from ginkgo biloba subjected to a simulated digestion
process,” Food Chemistry, vol. 86, no. 2, pp. 195–202, 2004.
[36] S. T. Chung, J. Ha, A. U. Onuzuruike et al., “Time to glucose
peak during an oral glucose tolerance test identifies predia-
betes risk,” Clinical Endocrinology, vol. 87, no. 5, pp. 484–491,
2017.
[37] M. Carmona, A. Zalacain, A. M. Sánchez, J. L. Novella, and
G. L. Alonso, “Crocetin esters, picrocrocin and its related
compounds present in Crocus sativus stigmas and Gardenia
jsaminoides fruits. Tentative identification of seven new
compounds by LC-ESI-MS,” Journal of Agricultural and Food
Chemistry, vol. 54, no. 3, pp. 973–979, 2006.
[38] M.-R. Calsteren, M. C. Bissonnette, F. Cormier et al.,
“Spectroscopic characterization of crocetin derivatives from
Crocus sativus and gardenia jasminoides,” Journal of Agri-
cultural and Food Chemistry, vol. 45, pp. 1055–1061, 1997.
[39] T. W.-M. Boileau, A. C. Boileau, and J. W. Erdman Jr.,
“Bioavailability of all-trans and cis-isomers of lycopene,”
Experimental Biology and Medicine, vol. 227, no. 10,
pp. 914–919, 2002.
[40] M. Evans, M. Beck, J. Elliott, S. Etheve, R. Roberts, and
W. Schalch, “Effects of formulation on the bioavailability of
lutein and zeaxanthin: a randomized, double-blind, cross-
over, comparative, single-dose study in healthy subjects,”
European Journal of Nutrition, vol. 52, no. 4, pp. 1381–1391,
2013.
[41] N. E. Moran, E. S. Mohn, N. Hason, J. W. Erdman Jr., and
E. J. Johnson, “Intrinsic and extrinsic factors impacting ab-
sorption, metabolism, and health effects of dietary caroten-
oids,” Advances in Nutrition, vol. 9, no. 4, pp. 465–492, 2018.
[42] D. Kostic, W. S.White, and J. A. Olson, “Intestinal absorption,
serum clearance, and interactions between lutein and beta-
carotene when administered to human adults in separate or
combined oral doses,” %e American Journal of Clinical
Nutrition, vol. 62, no. 3, pp. 604–610, 1995.
[43] D. M. Gustin, K. A. Rodvold, J. A. Sosman et al., “Single-dose
pharmacokinetic study of lycopene delivered in a well-defined
food-based lycopene delivery system (tomato paste-oil mix-
ture) in healthy adult male subjects,” Cancer Epidemiology,
Biomarkers & Prevention, vol. 13, no. 5, pp. 850–860, 2004.
[44] M. Shimoda, E. Kokue, T. Hayama, and T. B. Vree, “Effect of
albumin distribution,” Pharmaceutisch Weekblad Scientific
Edition, vol. 11, no. 3, pp. 87–91, 1989.
[45] T. L. Miller, S. L. Willett, M. E. Moss, J. Miller, and
B. A. Belinka Jr., “Binding of crocetin to plasma albumin,”
Journal of Pharmaceutical Sciences, vol. 71, no. 2, pp. 173–177,
1982.
[46] C. D. Kanakis, P. A. Tarantilis, H. A. Tajmir-Riahi, and
M. G. Polissiou, “Crocetin, dimethylcrocetin, and safranal
bind human serum albumin: stability and antioxidative
properties,” Journal of Agricultural and Food Chemistry,
vol. 55, no. 3, pp. 970–977, 2007.
[47] A. Eroglu, K. J. Schulze, J. Yager et al., “Plasma proteins
associated with circulating carotenoids in Nepalese school-
aged children,” Archives of Biochemistry and Biophysics,
vol. 646, pp. 153–160, 2018.
[48] E. Altinoz, T. Ozmen, Z. Oner, H. Elbe, M. E. Erdemli, and
H. G. Bag, “Saffron (its active constituent, crocin) supple-
mentation attenuates lipid peroxidation and protects against
tissue injury,” Bratislava Medical Journal, vol. 117, no. 7,
pp. 381–387, 2016.
8 Evidence-Based Complementary and Alternative Medicine
